Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

PSMA-vysoká: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

17. září 2026 aktualizováno: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

A Phase II Non-blinded Randomized Study Comparing External Beam Radiotherapy (EBRT), 177Lu-PSMA-617, and Short Term Androgen Deprivation Therapy (ADT) Versus EBRT and Long Term ADT in Men With High Risk Localized Prostate Cancer

This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6 months) is (1) safe and effective compared to standard of care alone, and (2) can reduce the side effects caused by long-term (24 months) ADT in men with high risk localized prostate cancer.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

Men with high-risk localized prostate cancer include those with stage cT3a or Grade Group 4/5 or Prostate Specific Antigen (PSA) >20 ng/mL, and the proportional rate of high-risk disease has increased to 20% of newly diagnosed patients in the US. These patients are currently recommended treatment with a combination of definitive radiotherapy and long-term androgen deprivation therapy (NCCN category 1) or radical prostatectomy with pelvic lymph node dissection. Radiotherapy most often consists of external-beam radiotherapy (EBRT) in 28 to 45 daily fractions with 1.5 to 3 years of ADT. Multiple phase III studies have shown a benefit in survival with long-term ADT. However, given the toxicities of long-term ADT, including fatigue, mood changes, sexual dysfunction, osteopenia, weight gain, diabetes and cardiovascular disease, many patients are reluctant to complete long-term ADT. This leads to significant demand for investigation of lower-toxicity alternatives to long-term ADT for patients with high-risk localized prostate cancer.

The combination of 177Lu-PSMA-617 with definitive EBRT and 6 months ADT for high-risk prostate cancer has the potential to increase the cumulative absorbed dose to the prostate, involved nodes, and micrometastatic disease, as well as decrease toxicity and improve QoL compared with EBRT and long-term ADT. ADT has been shown to increase radiosensitivity and PSMA expression of prostate cancer; therefore 6 months of ADT was selected to optimize the combination therapy while avoiding toxicities associated with long-term ADT. There are significant unknowns with respect to absorbed dose and toxicities of this potential combination of 177Lu-PSMA-617 and EBRT. In addition, the relative efficacy compared to EBRT plus long-term ADT is unknown. The investigators therefore propose a phase II randomized study of dosimetry, safety, and efficacy of Lu-177-PSMA-617, EBRT, and short-term ADT (6 months) in comparison with EBRT and long-term ADT (24 months).

Typ studie

Intervenční

Zápis (Odhadovaný)

60

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

  • Spojené státy
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21287
        • Nábor
        • Johns Hopkins University

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Mužský

Popis

Inclusion Criteria:

  • Patient must have high-risk prostate cancer (HRPC) defined by presence of exactly one high-risk feature: cT3a OR Grade Group 4 or 5 OR PSA > 20 ng/mL.

  • Histologic confirmation of adenocarcinoma of the prostate.

  • Patient must have localized HRPC defined by conventional imaging (no N1 disease by CT or MRI). Patients with or without intra-pelvic nodal metastases by PSMA-PET may be included as long as not enlarged >10mm short axis by conventional CT size criteria.

  • Patients must have PSMA-PET (68Ga-PSMA-11 or 18F-DCFPyL) with prostate tumor SUVmax > 10.

  • Patient must qualify for definitive treatment of prostate cancer including EBRT as well as ADT (up to 45 days of prior ADT is allotted).

  • Patient must be ≥ 18 years of age.

  • Patient must have a life expectancy ≥ 24 months.

  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

  • Adequate bone marrow reserve and organ function as demonstrated by complete blood count and chemistry panel completed within the prior 6 weeks demonstrating:

    1. Platelet count of >100 x109/L
    2. White blood cell (WBC) count > 3,000/mL
    3. Neutrophil count of > 1,500/mL
    4. Hemoglobin ≥ 10 g/dL
    5. Estimated glomerular filtration rate (eGFR) > 50 mL/min based upon Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation. Due to safety concerns relating to renal clearance and toxicity of 177Lu-PSMA-617, patients with estimated GFR between 50 - 60 mL/min will require a 99mTc-TPA GFR test and only patients with non-obstructive pathology will be included in the study.
    6. Total bilirubin < 3 x ULN (except if confirmed history of Gilbert's disease)
    7. Serum albumin > 30 g/L
    8. Aspartate aminotransferase (AST) < 3 times the ULN

  • For male patients with partners of childbearing potential, agreement to use barrier contraceptive method (condom) and to continue its use for 6 months from receiving the last dose of 177Lu-PSMA-617.

  • Patient must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Presence of a very high-risk feature: cT3b to T4 OR primary pattern 5 OR 2 to 3 high-risk features OR >4 cores with Grade Group 4 or 5.
  • Any prior pharmacotherapy (with the exception of up to 45 days of ADT prior to randomization), radiation therapy, or surgery as treatment for prostate cancer. Any prior radiopharmaceutical therapy.
  • Any prior radiation to the pelvis.
  • Presence of N1 or M1 disease by conventional imaging (CT, MRI, and/or bone scan) or M1 disease by PSMA-PET (68Ga-PSMA-11 or 18F-DCFPyL). Lymph nodes with short axis > 8 mm by CT will be considered N1 by conventional imaging.
  • Castration-resistant prostate cancer (CRPC).
  • Patient receiving any other investigational agents.
  • Patient is participating in a concurrent treatment protocol involving radiotherapy, surgery, or systemic anti-cancer agents.
  • Inadequate bone marrow reserve and organ function as detailed in 5.1.10.
  • Unable to lie flat during or tolerate PET/MRI, PET/CT or EBRT.
  • Concurrent serious medical condition that, in the opinion of the Investigator, would impair study participation.
  • Contraindication to receiving pelvic radiation, including history of or active inflammatory bowel disorders.
  • Refusal to sign informed consent.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Arm A (EBRT + 6 mo ADT + 177Lu-PSMA-617)

Participants will receive EBRT + 6 mo ADT + 177Lu-PSMA-617
Lék: EBRT + 6 mo ADT + 177Lu-PSMA-617

In Arm A, 177Lu-PSMA-617 will be given as intravenous infusion every 6 weeks, up to 4 cycles. Cycle 1 Day 1 (C1D1) of 177Lu-PSMA-617 will start at least 2 weeks after ADT, and EBRT will start at least 2 weeks after C1D1.
Aktivní komparátor: Arm B (EBRT + 24 mo ADT)

Participants will receive EBRT + 24 mo ADT
Záření: EBRT + 24 mo ADT

In Arm B, EBRT will start 3-7 weeks after Day 1 of ADT.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Rate of testosterone recovery (TR)
Časové okno: Post randomization up to 3 years.

The rate of testosterone recovery (TR) will be determined by the percentage of patients who recover normal T levels within 3 years after randomization.
Post randomization up to 3 years.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Biochemical disease-free survival (BC-DFS)
Časové okno: From randomization up to 3 years.

Measured from randomization to the time of a measured PSA value at least 2 ng/mL above nadir, and at least 25% above nadir, or death, whichever occurs first.
From randomization up to 3 years.
Time-to-Next-Intervention (TTNI)
Časové okno: From randomization up to 3 years.

TTNI is defined as the period of time from randomization to the initiation of any additional cancer-directed therapy. In the absence of a defining event, TTNI will be censored at the date of last visit documenting absence of interventions.
From randomization up to 3 years.
ADT-free survival (ADT-FS)
Časové okno: From randomization up to 3 years.

ADT-free survival defined as the time from randomization to the time of initiation of palliative ADT or death, whichever occurs first.
From randomization up to 3 years.
Metastasis-free survival (MFS)
Časové okno: From randomization up to 3 years.

MFS is defined as the time from randomization to the time of detection of at least one new metastatic lesions on conventional imaging. Patients who do not develop at least one new metastasis will be censored at the time of the last disease assessment.
From randomization up to 3 years.
Overall Survival (OS)
Časové okno: From randomization to the date of death, up to 3 years.

For subjects who do not die, time to death will be censored at the time of last contact.
From randomization to the date of death, up to 3 years.
Toxicity as assessed by adverse events
Časové okno: In Arm A, AEs assessed 7-10 days prior to every cycle of 177Lu-PSMA-617. In Arm B, AEs assessed at baseline, Day 1, EOT, and after the completion of EBRT. For both arms, starting at 6 months, AEs assessed every 6 months up to 5 years (no Month 54 f/u).

Toxicity of combination therapy with EBRT + 6 mo ADT + 177Lu-PSMA-617 by collecting CTCAE v5.0 adverse events.
In Arm A, AEs assessed 7-10 days prior to every cycle of 177Lu-PSMA-617. In Arm B, AEs assessed at baseline, Day 1, EOT, and after the completion of EBRT. For both arms, starting at 6 months, AEs assessed every 6 months up to 5 years (no Month 54 f/u).
Quality of Life as assessed by Expanded Prostate Index Composite (EPIC)
Časové okno: Pre-treatment, end of RT, 6 months, and every 6 months thereafter up to 5 years (no Month 54 f/u).

Score range, 0-100. Higher score better quality of life.
Pre-treatment, end of RT, 6 months, and every 6 months thereafter up to 5 years (no Month 54 f/u).
Quality of Life as assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30
Časové okno: Pre-treatment, end of RT, 6 months, and every 6 months thereafter up to 5 years (no Month 54 f/u).

Score range from 0 to 100. A higher score indicates better quality of life.
Pre-treatment, end of RT, 6 months, and every 6 months thereafter up to 5 years (no Month 54 f/u).
Quality of Life as assessed by Xerostomia Quality of Life Scale (XeQoLS)
Časové okno: Pre-treatment, end of RT, 6 months, and every 6 months thereafter up to 5 years (no Month 54 f/u).

Score range 0 to 60, with higher scores indicating worse quality of life.
Pre-treatment, end of RT, 6 months, and every 6 months thereafter up to 5 years (no Month 54 f/u).
Correlation of Toxicities and Absorbed Dose
Časové okno: In Arm A, AEs assessed 7-10 days prior to every cycle of 177Lu-PSMA-617. In Arm B, AEs assessed at baseline, Day 1, EOT, and after the completion of EBRT. For both arms, starting at 6 months, AEs assessed every 6 months up to 5 years (no Month 54 f/u).

To correlate rate of CTCAE v5.0 grade 3 toxicities with mean absorbed dose to normal organs at risk. Specifically, pelvic organ toxicities will be correlated with mean EBRT dose, mean Lu-PSMA absorbed dose and mean cumulative absorbed dose for the bladder, rectum, and bowel.
In Arm A, AEs assessed 7-10 days prior to every cycle of 177Lu-PSMA-617. In Arm B, AEs assessed at baseline, Day 1, EOT, and after the completion of EBRT. For both arms, starting at 6 months, AEs assessed every 6 months up to 5 years (no Month 54 f/u).

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Spolupracovníci

Novartis Pharmaceuticals

Vyšetřovatelé

  • Vrchní vyšetřovatel: Ana Kiess, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

17. srpna 2026

Primární dokončení (Odhadovaný)

1. srpna 2032

Dokončení studie (Odhadovaný)

1. srpna 2033

Termíny zápisu do studia

První předloženo

7. dubna 2026

První předloženo, které splnilo kritéria kontroly kvality

21. dubna 2026

První zveřejněno (Aktuální)

24. dubna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

22. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • J25104
  • IRB00494892 (Jiný identifikátor: Johns Hopkins Medicine IRB)

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit